2-[(3S)-3-[(1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[(3S)-3-[(1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
• 化学式: C₂₄H₂₈N₂O₅
• 分子量: 424.5
• InChiKey: XPCFTKFZXHTYIP-XJDOXCRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  31
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  95.9
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Process for Crystallization of Benazepril Hydrochloride
  申请人：Singh Girij Pal

  公开号：US20090082559A1

  公开（公告）日：2009-03-26

  An improved process for the crystallization of benazepril hydrochloride to obtain in at least 99.8% diastereomeric purity. The process comprises making a concentrated solution of benazepril hydrochloride in ethanol and adding the resulting solution to a non-solvent diisopropyl ether.

  一种改进的结晶苯扎普利盐酸盐的方法，以获得至少99.8％的对映异构体纯度。该方法包括在乙醇中制备浓缩的苯扎普利盐酸盐溶液，并将所得的溶液加入非溶剂双异丙醚中。
• COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA
  申请人：S-Form Pharma

  公开号：EP4023218A1

  公开（公告）日：2022-07-06

  Subject matter of the present invention is a combination medication for use in the treatment of a patient having acute and/or persistent dyspnea comprising at least two of the following components: a beta blocker, and one agent of the group consisting of an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II inhibitor and a combination of angiotensin II inhibitor or an angiotensin receptor-neprilysin inhibitor (ARNi), and mineralo receptor antagonist (MRA), gliflozine, a loop-acting diuretic, wherein a sample of bodily fluid of said patient has a level of BNP > 200 pg/mL and/or has a level NT-proBNP > 600 pg/mL, and wherein said sample of bodily fluid is selected from the group comprising blood, plasma and serum, and wherein said patient is either a patient with heart failure with left ventricular ejection fraction (LVEF) greater and equal to 40 %, preferably 50 %, or a patient with no heart failure.

  本发明的主题是一种用于治疗急性和/或持续性呼吸困难患者的复方药物，至少包含以下两种成分：血管紧张素转换酶（ACE）抑制剂、血管紧张素 II 抑制剂、血管紧张素 II 抑制剂或血管紧张素受体-肾素抑制剂（ARNi）和矿物质受体拮抗剂（MRA）的组合、格列酮类、环状作用利尿剂、其中，所述患者的体液样本的 BNP 水平大于 200 pg/mL，和/或 NT-proBNP 水平大于 600 pg/mL，且所述体液样本选自包括血液、血浆和血清的组，且所述患者为左室射血分数（LVEF）大于等于 40%（最好为 50%）的心衰患者或无心衰的患者。
• Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same
  申请人：Laboratory Skin Care, Inc.

  公开号：US10758478B2

  公开（公告）日：2020-09-01

  Uniform, rigid, spherical nanoporous calcium phosphate particles that define an internal space and an amount of active agent present in the internal space are provided. Also provided are topical delivery compositions that include the active agent loaded particles, as well as methods of making the particles and topical compositions. The particles and compositions thereof find use in a variety of different applications, including active agent delivery applications.

  本发明提供了均匀、坚硬、球形的纳米多孔磷酸钙颗粒，这些颗粒限定了内部空间和内部空间中的活性剂含量。此外，还提供了包括活性剂负载颗粒的局部给药组合物，以及制造颗粒和局部组合物的方法。这些颗粒及其组合物可用于各种不同的应用，包括活性剂递送应用。
• Compositions for treatment of heart failure in dogs
  申请人：Elanco Tiergesundheit AG

  公开号：US10874618B2

  公开（公告）日：2020-12-29

  The invention relates to a new fixed dose combination of benazepril with pimobendan.

  本发明涉及一种新的贝那普利与匹莫苯丹的固定剂量复方制剂。
• NEW COMBINATION
  申请人：Novartis AG

  公开号：EP2793866A2

  公开（公告）日：2014-10-29